If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
The hydrostatic effect of variable ballast tanks is not the only way to control the submarine underwater. Hydrodynamic maneuvering is done by several control surfaces, collectively known as diving planes or hydroplanes, which can be moved to create hydrodynamic forces when a submarine moves longitudinally at sufficient speed. In the classic cruciform stern configuration, the horizontal stern planes serve the same purpose as the trim tanks, controlling the trim. Most submarines additionally have forward horizontal planes, normally placed on the bow until the 1960s but often on the sail on later designs, where they are closer to the center of gravity and can control depth with less effect on the trim.
Anne S. Ulrich (born December 31, 1966) is a German chemist. She is the director of the Institute of Biological Interfaces (IBG-2) and Chair of Biochemistry at the Karlsruhe Institute of Technology. She studied chemistry at the University of Oxford - continued her doctoral work in the laboratory of Anthony Watts - held subsequent research positions as an EMBO-Fellow with Hartmut Oschkinat at the European Molecular Biology Laboratory in Heidelberg and as a Liebig-Fellow with Felix Wieland at the University of Heidelberg - became Associate Professor at the University of Jena - until she moved her group in 2002 to the Karlsruhe Institute of Technology. Her research focuses on the structural and functional analysis of biomembranes by solid state NMR. The main systems of interest are:
To enhance sensitivity, the secondary capillary of the nano-DESI probe can be equipped with a nebulizer, which takes benefit of the Venturi effect, facilitating the aspiration of the liquid. This enables the secondary probe to be longer, while still maintaining stable electrospray, thereby simplifying the setup process. Moreover, it offers greater versatility in nano-DESI solvent selection, allowing water to be used as an extraction solvent. This expands the technique’s chemical coverage and enhances the customization of solvent components for selective extraction of polar compounds. Additionally, the capillaries can be integrated into a custom 3D-printed cassette, creating a convenient plug-and-play device.
=== Waste disposal === The long half-life of technetium-99 and its potential to form anionic species creates a major concern for long-term disposal of radioactive waste. Many of the processes designed to remove fission products in reprocessing plants aim at cationic species such as caesium (e.g., caesium-137) and strontium (e.g., strontium-90). Hence the pertechnetate escapes through those processes. Current disposal options favor burial in continental, geologically stable rock. The primary danger with such practice is the likelihood that the waste will contact water, which could leach radioactive contamination into the environment. The anionic pertechnetate and iodide tend not to adsorb into the surfaces of minerals, and are likely to be washed away. By comparison plutonium, uranium, and caesium tend to bind to soil particles. Technetium could be immobilized by some environments, such as microbial activity in lake bottom sediments, and the environmental chemistry of technetium is an area of active research. An alternative disposal method, transmutation, has been demonstrated at CERN for technetium-99. In this process, the technetium (technetium-99 as a metal target) is bombarded with neutrons to form the short-lived technetium-100 (half-life = 16 seconds) which decays by beta decay to stable ruthenium-100.
Sources: en.wikipedia.org
Independent scholar Mikhail Berg compared the war in Georgia to the German occupation of Czechoslovakia where the Sudeten Germans refused any offers of autonomy and instead were provoking the Czechoslovak authorities until the latter was forced to use force and then Germany intervened. Historian Boris Vadimovich Sokolov also made a similar comparison of the Russian attack on Georgia with the German annexation of Sudetenland. In August 2008, Aleksandr Golts, a Moscow-based defense analyst stated, "Russia's policies over the past several years caused this war. And for this they bear responsibility." In August 2008, Yulia Latynina, Russian journalist, observed when the Georgians took the Sarabuk height, from which the military movement from Ossetian-controlled Java to Ossetian-controlled Dmenisi could be observed, the exchanges became frequent. By that time, Java had been turned into a military base, located beyond the demilitarised zone, where any amount of artillery and armored vehicles could be deployed. Latynina suggested that the main aim of the Georgian army was not Tskhinvali, but Java and to block the Transcaucasian Highway above Java since the Roki Tunnel could not be blown up. If Java had been taken by the Georgians, then Saakashvili would have exposed the arsenal stored there to the world, which Russia could not allow. In August 2008, Georgy Satarov, head of the InDem Foundation, said: "President Medvedev sent troops to the Georgian-Ossetian conflict zone without approval of the Federation Council.
=== Validation === Validation is intended to ensure a product, service, or system (or portion thereof, or set thereof) results in a product, service, or system (or portion thereof, or set thereof) that meets the operational needs of the user. For a new development flow or verification flow, validation procedures may involve modeling either flow and using simulations to predict faults or gaps that might lead to invalid or incomplete verification or development of a product, service, or system (or portion thereof, or set thereof). A set of validation requirements (as defined by the user), specifications, and regulations may then be used as a basis for qualifying a development flow or verification flow for a product, service, or system (or portion thereof, or set thereof). Additional validation procedures also include those that are designed specifically to ensure that modifications made to an existing qualified development flow or verification flow will have the effect of producing a product, service, or system (or portion thereof, or set thereof) that meets the initial design requirements, specifications, and regulations; these validations help to keep the flow qualified. It is a process of establishing evidence that provides a high degree of assurance that a product, service, or system accomplishes its intended requirements. This often involves acceptance of fitness for purpose with end users and other product stakeholders. This is often an external process.
==== Never marketed ==== Alaproclate (GEA-654) Cericlamine (JO-1017) Desmethylcitalopram Didesmethylcitalopram Femoxetine (FG-4963; Malexil) Ifoxetine (CGP-15,210-G) Omiloxetine Panuramine (WY-26,002) Pirandamine (AY-23,713) RTI-353 Seproxetine ((S)-norfluoxetine)
Sources: en.wikipedia.org
l-DOPA was first isolated from the seeds of the Vicia faba (broad bean) plant in 1913 by Swiss biochemist Markus Guggenheim. The 2001 Nobel Prize in Chemistry was also related to l-DOPA: the Nobel Committee awarded one-quarter of the prize to William S. Knowles for his work on chirally catalysed hydrogenation reactions, the most noted example of which was used for the synthesis of l-DOPA.
A photograph of the deceased in good health is often sought to guide the embalmer's hand in restoring the body to a more lifelike appearance. Blemishes and discolorations (such as bruises, in which the discoloration is not in the circulatory system, and cannot be removed by arterial injection) occasioned by the last illness, the settling of blood, or the embalming process itself are also dealt with at this time (although some embalmers utilize hypodermic bleaching agents, such as phenol-based cauterants, during injection to lighten discoloration and allow easier cosmeticizing). It is also common for the embalmer to perform minor restoration of the deceased's appearance with tissue building chemicals and a hypodermic syringe. Tissue building chemicals (Tissue Builders) become solid with the introduction of liquids such as water or interstitial fluids. Commonly the area where the sphenoid and temporal bones meet; this can also be referred to the temples. In the event of trauma or natural depressions on the face or hands, tissue builder can also be utilised to return those regions of the face to the expectations of the family.
==== Pancreatic extracts before insulin ==== The limit to early diabetes control was partly due to the common-sense assumption that the stomach was wholly responsible for nutrient metabolism. As physiologists came to better understand the metabolic role of other organs, they began to hypothesize alternative causes for the disease. Through accumulating evidence, it was established that the "cause" of diabetes could be localized to the pancreas, then to its internal secretion (see: History of diabetes#Pathophysiology#Role of the pancreas). These findings fueled attempts to treat diabetes in animals and humans with direct extracts from the pancreas, by no less than 400 researchers according to historian Michael Bliss. In the early 1900s, Georg Ludwig Zuelzer experimented extensively with pancreatic extracts. After initial tests on rabbits, he injected his extracts (which he called acomatol) on humans to clear but inconsistent success and severe side-effects. He nonetheless took out an American patent on his yet-problematic extracts. Unfortunately, Zuelzer was ultimately unable to purify the extract due to difficulty obtaining pancreases, a lack of funding, and interruption by World War I. Ernest Lyman Scott, studying at the University of Chicago between 1911 and 1912, also obtained some promising results but was discouraged from continuing. In 1913, John MacLeod, at the time several years into research in the area of carbohydrate metabolism and blood sugar behaviour, synthesized the state of research in Diabetes: Its Pathological Physiology.
This change in infrastructure may alter cell shape and behavior and is often used to transport vesicles, pathogens, or other related structures. Actin filament crosslinking Results in the overall stabilization of the actin filament network. The cell utilizes crosslinking proteins are various sizes to accomplish different means of stability within the binding network. Relatively small ABP's such as scruin, fimbrin, and espin function by solidifying actin filament bundles. Larger ABPs that exhibit coil-like qualities such as filament function in the promotion of orthogonal organization. As a whole, actin crosslinking provides framework for which the cell may transport signaling intermediates needed for other steps within the actin remodeling cycle. Actin filament contraction and cargo motoring Represents the ability for the actin filament network to react to environmental conditions and respond through various forms of vesicle and signal trafficking. Most commonly, the myosin protein exists as a "motor" that escorts cellular "cargo" throughout the cell. Myosin, primarily Myosin II, is also essential to the generation of contractile forces amongst the actin filaments. Membrane attachment to actin network Attachment of the actin-orthogonal network to the cell's membrane proves essential to the locomotion, shape, and mechanical function of the cell. The dynamic nature of a cell remains directly related to the actin-filament network's ability to respond to the contractile forces that result from environmental and internal cues.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.